Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates.
Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates.
复制标题
B组链球菌囊类型，序列类型和表面蛋白作为潜在疫苗候选物的系统评价。
DOI：
10.1016/j.vaccine.2020.08.052
复制
发表时间：
2020-10-07
期刊：
影响因子：
5.5
通讯作者：
Lawn JE
中科院分区：
文献类型：
--
作者：
Bianchi-Jassir F;Paul P;To KN;Carreras-Abad C;Seale AC;Jauneikaite E;Madhi SA;Russell NJ;Hall J;Madrid L;Bassat Q;Kwatra G;Le Doare K;Lawn JE
至2018年B组链球菌血清型的最全面综述。B族链球菌菌株类型和蛋白质数据的首次系统性综述。理论上，候选疫苗可以保护93-99%的致病菌株。需要对低收入和中等收入国家的GBS菌株进行更多研究。据估计，全世界有2100万孕妇（18%）携带B族链球菌（GBS），这是新生儿、孕妇和死胎中侵袭性疾病的风险。≥ 60岁或有基础健康状况的成人也容易患侵袭性GBS疾病。我们对GBS生物特征进行了系统评价，包括：荚膜多糖（血清型），序列类型（多位点序列类型（MLST））和毒力蛋白。我们综合了高危人群的数据，为疫苗开发提供信息。我们进行了系统回顾和荟萃分析，以估计高危人群中GBS血清型的比例：孕产妇定植、孕妇浸润性疾病、死产、0-90天婴儿和老年人（≥60岁）。我们考虑了区域变化和时间趋势（2001-2018）。对于这些高危人群，我们总结了报告的MLST和表面蛋白。基于198项研究（29247株），93-99%的GBS分离株为血清型Ia、Ib、II、III、IV和V。可能存在区域差异，但数据缺口很明显，即使对于拥有最多数据的母体定植也是如此。血清III型在婴儿侵袭性疾病（60%）和GBS相关死产（41%）中占主导地位。ST 17占婴儿侵袭性疾病的高比例（41%; 95%CI：35-47），并且几乎仅在血清型III菌株中发现，较少存在于母体定殖（9%; 95%CI：6-13）、婴儿定殖（4%; 95%CI：0-11）和成人侵袭性疾病（4%; 95%CI：2-6）中。具有alp 1、alp 2/3、alpha C或Rib表面蛋白靶点中的至少一种的菌株的存活率为87%的母体定植、97%的婴儿定植、93%的婴儿疾病和99%的成人侵袭性疾病。在所有菌株中至少报告了三种菌毛岛蛋白中的一种。六价疫苗（血清型Ia、Ib、II、III、IV和V）可全面覆盖所有高危人群。对循环的致病靶蛋白的监测可用于告知疫苗不靶向荚膜多糖。解决数据差距，特别是世界区域和一些高危人群（特别是死产）的数据差距，是疫苗设计过程中循证决策的基础。
Most comprehensive review of Group B Streptococcal serotypes through 2018. First systematic review of Group B Streptococcal strain type and protein data. Theoretically candidate vaccines may protect against 93-99% disease-causing strains. More studies on GBS strains in low- and middle-income countries are needed. 21 million pregnant women worldwide (18%) are estimated to carry Group B Streptococcus (GBS), which is a risk for invasive disease in newborns, pregnant women, and stillbirths. Adults ≥ 60 years or with underlying health conditions are also vulnerable to invasive GBS disease. We undertook systematic reviews on GBS organism characteristics including: capsular polysaccharide (serotype), sequence type (multi-locus sequence types (MLST)), and virulence proteins. We synthesised data by at-risk populations, to inform vaccine development. We conducted systematic reviews and meta-analyses to estimate proportions of GBS serotypes for at risk populations: maternal colonisation, invasive disease in pregnant women, stillbirths, infants 0–90 days age, and older adults (≥60 years). We considered regional variation and time trends (2001–2018). For these at-risk population groups, we summarised reported MLST and surface proteins. Based on 198 studies (29247isolates), 93–99% of GBS isolates were serotypes Ia, Ib, II, III, IV and V. Regional variation is likely, but data gaps are apparent, even for maternal colonisation which has most data. Serotype III dominates for infant invasive disease (60%) and GBS-associated stillbirths (41%). ST17 accounted for a high proportion of infant invasive disease (41%; 95%CI: 35–47) and was found almost exclusively in serotype III strains, less present in maternal colonisation (9%; 95%CI:6–13),(4%; 95%CI:0–11) infant colonisation, and adult invasive disease (4%, 95%CI:2–6). Percentages of strains with at least one of alp 1, alp2/3, alpha C or Rib surface protein targets were 87% of maternal colonisation, 97% infant colonisation, 93% infant disease and 99% adult invasive disease. At least one of three pilus islands proteins were reported in all strains. A hexavalent vaccine (serotypes Ia, Ib, II, III, IV and V) might provide comprehensive cover for all at-risk populations. Surveillance of circulating, disease-causing target proteins is useful to inform vaccines not targeting capsular polysaccharide. Addressing data gaps especially by world region and some at-risk populations (notably stillbirths) is fundamental to evidence-based decision-making during vaccine design.
登录
查看更多内容
影响因子：
5.2
作者：
Campisi E;Rosini R;Ji W;Guidotti S;Rojas-López M;Geng G;Deng Q;Zhong H;Wang W;Liu H;Nan C;Margarit I;Rinaudo CD
通讯作者：
Rinaudo CD
影响因子：
6.2
作者：
Dangor, Ziyaad;Kwatra, Gaurav;Madhi, Shabir A.
通讯作者：
Madhi, Shabir A.
DOI：
10.1093/cid/cix661
发表时间：
2017-11-06
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Bianchi-Jassir F;Seale AC;Kohli-Lynch M;Lawn JE;Baker CJ;Bartlett L;Cutland C;Gravett MG;Heath PT;Ip M;Le Doare K;Madhi SA;Saha SK;Schrag S;Sobanjo-Ter Meulen A;Vekemans J;Rubens CE
通讯作者：
Rubens CE
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
6.4
作者：
Bellais, Samuel;Six, Anne;Poyart, Claire
通讯作者：
Poyart, Claire